Curis (CRIS) 8 Feb 242023 Q4 Earnings call transcript

Company Profile

Participants

Diantha Duvall	executive
James Dentzer	executive
Edward White	analyst
Soumit Roy	analyst
Li Wang Watsek	analyst
Yale Jen	analyst
Billal Jahangiri	analyst

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to Curis' Fourth Quarter 2023 Business Update Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Diantha Duvall, Curis' Chief Financial Officer. Diantha, please go ahead.

Diantha Duvall

Thank you, and welcome to Curis' Fourth Quarter 2023 Business Update Call.

business would section encourage www.curis.com of our quarter I to to to begin, related fourth Investors and our our XXXX we like everyone to go find financial Before tables. release update website at

and that may These like be we to statements statements, are are everyone forward-looking differ current our risks the based call, subject I would on remind uncertainties, expectations during results also which to materially. and will actual making and certain beliefs.

filings. SEC our see please details, additional For

me are Zung, Chief Development Joining call Executive Officer; Officer. and today's Dentzer, President on Jim and Chief Jonathan

question-and-answer We at will also be available end for call. a our period of the

to -- like the to turn call over I'd now Jim. Jim? I'd to like

James Dentzer

headwinds struggling to partial challenge Diantha. faced welcome and a everyone, of and with was that Good in industry past leukemia Quarter biotech look stalled to a our back you, the Curis over market. Business the grim FDA. months. all hold with seeing morning, whole today's study I'd the daunting start Entering XXXX, the financial the call of Fourth of Thank like XX clinical on Curis' Update Call.

FDA. in In questions to the analyses. tirelessly team the posed adversity, rose XXX of We additional worked by and face Curis challenge. patients enrolling performing additional that the This the at BID included answering milligrams

partial on the result, we of dosing optimal the regimen than alignment hold profile safety the expected. for quarter gain removal earlier a As and emavusertib, were able the a to of monotherapy secure full confirm clinical

relapsed/refractory have FLTX and going mutation. targeting a update well In we is reopening AML We midyear. of then are data monotherapy and our quite expect our study, clinical enrolling sites population a Enrollment we to by or with patients patients. a to energy spliceosome redirected genetically-defined new

progress study in this is regardless from preliminary AML that a status. of emavusertib in study second Italy, study with initiated their venetoclax and all Germany in leukemia. of half and we Spain, of data study being of combination in conducted patients azacitidine we for a frontline this and sites mutation advances, year. have While year in at all, expect All the terrific This

physicians our program, to equally high interest. efforts data focused the enrollment. data. combination Dr. initiated indication We San Greg clinical the Diego. data multiple an turn collected NHL present level on which lymphoma, lymphoma in December, is we subtypes, sites, and of conference ASH across let's initial were from in especially we reviewing at the or pleased ibrutinib. at with Mayo our Clinic evaluating Now terrific, ASH released are And in PCNSL Tun to The Nowakowski, CNS the After in primary emavusertib where PCNSL, we ultra-orphan identified key with new were had Han and of we relapsed/refractory we generating Dr. meetings have

reminder, frontline were It PCNSL of no As In high-dose works, of treatment treatment. patients longer to remission a methotrexate X small chemo. our is there patients. is their number is approved a X of and in study, complete admittedly no disease. When achieve able that second-line

encouraging. very was community clinical the from interest and response the However,

across In since and weeks clinical the from calls wanting Europe team fielding our participate our sites the X ASH, trials. in been has to U.S.

emavusertib, reflection reflection where also we to but of be Obviously, have efforts we the by of of a QX, indefatigable expect end sites the clinical a team. the Curis couldn't of In excitement a is more doubled the them. of this is the number fact, of it ago. proud versus I year were about

an XXXX, and short, done the the potential momentum solid In melanoma. expand emavusertib forward incredibly this of continuing entered agreement pembrolizumab we into look explore we opportunity that investigator-initiated study tumors. that We're patients to to upon the to NCI announced an we we for December, in productive study to presents research an and in the centers trial and in combination metastatic of had in Finally, emavusertib at that with academic excited XXXX. an

Diantha? I'll results With the quarter. financial that, to back turn call review over to the for Diantha our

Diantha Duvall

Jim. Thank you,

the For reported million a million same of of million months XXXX, Curis net share share $XX.X XXXX, $X.XX compared December XXXX. for as as months $X.XX the per of for $XX.X to per the $XX million the net a million compared of million loss share $XX.X for for to ended period XX, $X.XX per December same period compared share of in $X.X a to ended loss quarter net XXXX. Revenues quarter $X.X million XX or loss Curis compared net fourth XXXX. XXXX. of or in per the a fourth Revenues to net million in for in loss XXXX, period for XX same $XX.X were the or net $XX.XX XXXX $XX.X reported XX, the or were

XXXX. higher to expenses by driven was development XX, in and $X.X costs. XX The in million Research December in the quarter was $XX were of for clinical for to R&D $XX million fourth XXXX compared $XX.X XXXX, R&D million XXXX. increase compared ended the million months development

for December consulting to General quarter driven $XX.X administrative million million in compared by legal professional, XX, G&A to the months G&A XXXX. million in and $XX.X XXXX, higher the The XXXX. expenses XXXX services. primarily compared $X.X ended was for in and XX were fourth of increase $X.X million was

the expense Other royalties. for expense the XXXX, and net XX, million related was net was of XXXX. $X.X the expense ended expense to million December net interest income to compared future for net of of income months Other $X.X XX $X.X other sale 'XX. fourth in noncash in million of consists income quarter Other compared of income XXXX other net million $X.X to

million, of cash, and XXXX, equivalents and investments approximately million of there outstanding. $XX.X Curis' totaled As cash XX, stock December shares were X.X common

and enable I'd be equivalents cash will into planned the that to cash investments open a call for Operator? questions. continue We like operations existing expect XXXX. With our in position and solid our cash, that, to

Operator

will first Ed Wainwright. question our And come H.C. of Instructions] White from [Operator

Edward White

you CNS and open. is last Jim, how you time sites the you open lymphoma trial, the can many know how sites clinical many doubled this us wondering versus I'm plan just you to let mentioned that that sites if in year. have primary

James Dentzer

of We try the our this any of think of increasing get the time busy. of conference reason encouraged saw I in we given we're call mentioned at very that a is number And data them. were ourselves. if to you because it's was we because, the But why reflection of of in Obviously, always the you incredibly kind were details have that we booth ASH, course, out that we by had. sites the

running got, not as I sites And able not enthusiasm we've by followed by and online. broadly that's the up these the But been and of being new in to U.S. end across said, double world, just to but expectation the more QX, get up the

exciting it's So our perspective, really can that and hopeful I'm that from we going forward. momentum keep

Edward White

thoughts that give primary market? CNS on you your the lymphoma can us size of And

James Dentzer

ultra-orphan we an the reasons It's one It's Sure. selected market. of it. why

So only path. we one lot think you been one if path. a use where lymphoma, the that Anytime have targeting across pathway. that everywhere gets the of inhibitors regulating you of non-Hodgkin's of course, and There BTK, the broadly. other BTK used, from NF-kappaB We're targeting are BTK targets down landscape you're

a because on conversations When primary first CNS within we in in it's lot non-Hodgkin's very landscape of look incidence we development aggressive regulatory the across -- perspective, the also benefits X can a lymphoma, disease so with of we we lymphoma focused a small, especially it's authorities. That CNS primary of we can from quickly. But believe fairly per address where attractive lymphoma, yields million.

first data, the in saw in the X responses, the few you As a we treatment. complete X months X on got of that or

very that's helpful. So

And relapsed/refractory of no treatments. are approved drugs course, PCNSL. effective There there no are for

is can we of there can no and response see this if the it's encouraging. a ultra-orphan, are treatments we disease approved So go from drug, where after really that kind

Edward White

get a And I I picture solid thoughts the if big in potential to ask tumors. could your on perhaps question. just wanted

You in thoughts had the in beginning just that mentioned -- I on market solid your tumors KEYTRUDA large with with in metastatic -- in combination to IST wanted get overall. melanoma.

James Dentzer

Yes.

solid is really exciting. So tumors

more of identifying was discovered no things this that target, one about. that been, role have was so the one oncology from very Curis that had was of beginning in and the broadly exciting knew the else of IRAKX We course, something in

solid So dollar one we revenue multibillion had some do template after knows Pharmacyclics the mind go yet. else designed of effective it the indication would in in what no an designing and also were be would you tumors. how leukemia we And about that but with so in we in or potential, molecule originally, competitive a advantage when that blockbuster indication molecule confer lymphoma,

And targeted that's course, we those and in data the population that's, As the where in gone our spliceosome to The you We've and data studies and started really we lymphoma, know, IRAKX are or our the started as frontline expect in in look compelling. in lymphoma would population, really is first tumors. study. your the of into most melanoma, then just we've to first this recent time hit compelling. solid point, that data -- population well, FLTX the

done a and types NCI studying centers the there's tumors. of been Now work lot by in academic emavusertib of various by solid in

to of solid in our lot a looks for There IRAKX on, are where role time plays in confer bladder is tumors in first ovarian, know number it and of we So example, work might where in benefit. This cancer, into going able we're be different lung, in interesting that. a a cancer, there's drug pancreatic. like gastroesophageal the going significant

of all it's individually benefit level a tumors that really that idea markets the provide very world that of exciting. drug quite solid are. about could to at But a in targeted human little we no large talk of other have high premature how though drug course, is the I does incremental these the looks it across as markets and think those

Edward White

question, the last could. if And I

your at? fund tumors is get you'd you the down Is partnering as that thoughts expand solid be road? something into in you tumors. think on looking could something to your you wanted the this that that Just solid product going on own Or

James Dentzer

Sure.

as for. a take most rather drug is trials, that's lot PD-X, pembro, consider maybe study combination mean, we it of PD-X. So now a going of which clinical would trials a There people a with of right are pay Merck's I study There on in in the point. lot case Obviously, company's are melanoma X,XXX. deleting the not

and drug, they give free is But they the study. way work most to the those run then Merck beg them of

opposite. study, one Merck's the going the study. picking have tab this free providing We the and for get up data one to we're We're the drug. the from

companies drug. now minimum, we're in we'd number leukemia clinical that solid lymphoma like in what the studies free would in for or we or it's obviously, getting expand most to is whether the XX-XX study. going So get at can run, to of just hope tumors Ideally, if a

of data all have up find it's I XXX% opportunity at future that we're optimistic partner our going to really overly it. be to this without tumors, think obviously, we're we're and across do the any the to time, to afford in get going giving by leukemia studies that now lymphoma, and solid can to rights. But are able excited funded we point

can and show keep to such So significant our I drug we this as afford long that's rights has plan. data that our the that think as generate potential,

Operator

comes next The Roy question Soumit from of JonesTrading.

Soumit Roy

on fronts. the triple the progress with front question on multiple combo Congratulations venetoclax. line, and the emavusertib, on One HMA all

different U.S. starting also? trial countries second... planning -- Europe. initiating including X you some The mentioned You're on Are you sites

James Dentzer

Go ahead.

Soumit Roy

in still patients? are planning that combination is Trials, monotherapy emavusertib to Or do you ibrutinib? of

James Dentzer

Okay.

first one the first. So

tertiary we data prove where to quickly preclinical we the in that the in half patients, early primary that of driver the of XXXX, study data of article know, sites driver initial article disease, thing get pointed the generate a in the that want it's of you patients. it's stages, driver. a patients, quickly. all other works. We've disease. disease a lot we're that can is the published driver the #X triplet got of AML we most we or that and the Smith, really not as suggests can for of So There's to is is half -- the secondary Nature of think some in this as Choudhary relatively published out. these the but IRAKX as important triplet, Because #X Half all data In targeting was

from a So no really, drug other does. provide incremental benefit that this mechanism new should

go term of care. many long azacitidine is That's can course, with the of combination we capture in venetoclax. So to, and to patients as standard frontline as

the care in of So is be of recapitulate This aza-ven would the hope that lab, found aza humans emavusertib can efficacy add we standard or ven treatment. in our to to we or whether that and the that significantly what you increases combo.

are again, And And want what quickly, Aza course, So if we the in tough safety. all but they're to clinic. go regimen as you that to a to check Anecdotally, and identify we effective, that's what of we have want tolerate. found They're lab. that's half for of doublet always ven, pretty know, to and pretty in tolerate. aza-ven discontinue try that very possible, treatment. tough to on the patients

to the And safety kind And study. focus sites of going a confirming we're if expect. and to that overlap early in those patients signal. are you is efficacy that no want on what you be for of it to chosen to really can way, the sites So going on to do identify that putting second, the that quickly, initiate and very looking is exploration then be we've that course, in helps concentrated there we days we're as doing

you could question, second me? remind Your

Soumit Roy

fully Yes, I understand.

you so you combine plan to want get ] frontline expecting So on What's PCNSL venetoclax you to the that, with to to or the patients? here? trial, If get are ibrutinib? [ want

James Dentzer

No, thank for thank you you, that.

the the case of of now, the that clear. it's point. And for, the initial right the is problem starting And the first, patients ema for rationale combination again, NF-kappaB NHL emavusertib driving So ibrutinib, lymphoma, patients. and with and relapsed is overactivity. combination In that's refractory one's disease ibrutinib, in and

process overactive, NF-kappaB the of is disrupts apoptotic is malignant when what cells. So it happens the

driving after fact, now billion What the drug. on of NF-kappaB that you of on pathway, billion inhibitor pathway of them overactivity. We $XX that's pretty inhibitor that know, market driving $XX effective. a to X are in way, that, J&J BTK a high companies the pharma And in covalent that are BCR get on that, as you X various inhibitors. the can. effectively So it's looking There them a the we you're if is blocking big know inhibitors is now hit all as reason blocks it of BCR we're working rate X or BTK to as BTK chasing of is AbbVie, hard pathways lymphoma do BTK which all you're same flavors, NF-kappaB. response billion ibrutinib that itself noncovalent, today, is today, NF-kappaB $XX

Toll-like in the and the path and IRAKX, receptor that the pathway, that's currently second is shut a absence is It that of MyDXX Myddosome The without broadly company pathway drug that to Curis only that blocks path, has more binding, the emavusertib. receptor unaddressed. down. Myddosome binds Toll-like

to NF-kappaB reason to So when back, down it the that's step by you strongly can. NF-kappaB BTK, have regulate lymphoma if treated you stands as effectively you'll block as you always or want

either So with alone. we what always so combination, lab. IRAKX. clinic. hit what the better monotherapy, path not than And we're course, the of BCR combination path The receptor should the in with Toll-like BTK, in one that's found be the that's the And far hit finding

So that's with the the logic emavusertib. for combination

to it frontline to an that And across that. with we're for think, inhibitors. as We've we've primary CNS line premature it's explore opportunity to with line, front go BTK can going our we're of indication chosen to a long-term able going front non-Hodgkin's generate the we that data eventually, suggest is standard want quickly. But lymphoma show prove course, of in little pretty to out. of is, companion care to Now long would have been to going terms of I We BTK that combination lymphoma? term, proof-of-concept In like possibility to a course. this

a now, setting For regulatory opportunity. approved, should go there the no where pretty compelling indication ultra-orphan that where can an having into are we drugs offer relapsed/refractory

we're I that's it helpful. why So path. that hope going down was

Soumit Roy

inside speaking to IRAKX you're for moving the that market, helpful space eventually leukemia if going in forward tumor, tumor solid diagnostic would and both also companion, the I'm assay of got carving into companion if the it. -- since push solid curious we And setting. of be in mutation you're No, and the kind the for

James Dentzer

Yes.

complicated. a the short long is So The little it's answer is answer yes. more

identification regulatory answer answer, is short a diagnostic for companion IRAKX for the in expression? the So we and pursuing are The yes, absolutely. path the

our path the slow we is making want more patients. and drug -- development to available don't In for to this down complicated that answer

in have into path So patients IRAKX in going overexpression. the spliceosome we're looking we're monotherapy or fastest side leukemia either an population that ensuring the go way using a focus to FLTX mutations. We're that where the is mutation to IRAKX

Now gene mutations panels. spliceosome are you'd subset patients overexpress a that reason existing go mutations of mutations identified in IRAKX. after why spliceosome The already those are is

to have MD panel, like panel. Illumina panel, have new easier. So We existing that assay into much Anderson We the FoundationOne just panels, gene IRAKX. need a a places don't companion the can is lean a the identifying proprietary diagnostic

term, These run and that we on of our It's can frontline in going going to if use say mechanism. panels diagnostic. existing IRAKX patients, go going diagnostic. as that a course, we But we're expression have for mutations of where and combination. companion specific won't these longer by lean one their you to and want a have are need comers all definition, already into you We're the logic

Operator

next Watsek The Li comes of from Fitzgerald. Cantor question

Li Wang Watsek

for we as going guess, for to a the the bit with data expectations set going that the I just for data little set from are you're bar to well midyear, leukemia present X study for the as is the what see, maybe Jim, that around mutations? spliceosome us

know, and data alluded it's combo to us tell also, expect about that's bit the pretty regimen? aza-ven, second with overlapping any is And bar effective. high, half of Because little the about bar tox toxicities, here. this we you you the for to earlier then do And a fairly maybe going come year, as as this

James Dentzer

in. dialing Li. Yes. I you Thank you, appreciate

consistently at XX in have in patients data to terms set data target set XX, of like course, range. I where We'd in going equals patients, and collected. somewhere CNS. to to XX got have we'd of the patients. We that of of X patients to said set first, like dose spliceosome, we've questions, a X a we're XX what to increase to FLTX X in now that in those on position our data So is of primary data a we've patients, be in -- that hope number

and would data them, have level you responses. of and period in of them for patients, to -- by leukemia, position year-end. and that then a FLTX spliceosome course, of treat is the a midyear the we by level time assess lymphoma My enroll be that in in hope Of that follow and

the In But we're do think side we rate is the in very to spliceosome is XX%, we for effective we terms in leukemia, what need FLTX benchmark, compelling. rate be a XX% or bound. bound either a XX% CR/CRh in line of kind of lower of lower salvage to monotherapy teens, think CR/CRh XX%, in low the targeting therapy,

first look of X our let's get course, ourselves. better than patients. It's only Of patients But that. X ahead not

XX compelling. to hope get to we can is what XX% patients, and that rate CR/CRh clear XX As really that of we'd we be

On a there available What side, the for the we is monotherapy existing BTK do is XX%. a was of bar study the lymphoma XX as was that probably CR set patients, data in lower. are because CNS treatments, know largest that rate lymphoma no primary

population. BTK-naive wouldn't patients work they've again probably in XX% that you'd X roughly So BTK yet of patients. Once CR again, in out at you'd all. expect that rechallenging expect at BTK, or X failed And with them that's rate

X I encouraging. that compelling discussion out data far rate. X. think getting to set rate in of if to patients, in expect X I maintain FDA. X higher very don't we a a we've CR we're highly have need a of maintain with or think BTK-experienced we quite is might that lymphoma, got obviously That out But XX% can You so

what lymphoma that We to patients XX year-end. for to for XX Was a sorry, XX have for. leukemia is indications range and -- XX in in to So by look we're all helpful? in that position to be hoping I'm data midyear by

Li Wang Watsek

And overlapping toxicities with...

James Dentzer

yes. yes, Yes,

to look in the for that's So #X triplet. thing the

everywhere very able got makes clear that it our you deck, way the were reason really exploration that. The that if mechanism consistency to leukemia from part a triplet is we've efficacy the clinic making I'd efficacy the data it's toxis merit aza-ven it's add Of overlapping high would of expect we And tested, sure some we've aza-ven. perspective, add no that see looks data, the in -- same say, in to safety else to corporate adding less to don't would the lab, preclinical that sense nice knowing There that worked profile. our it it the works to preclinical it we would tolerable be on -- it. in like looked an to really any if We saw is from based lab know. and we aza, we that to course, that emavusertib at that outline that in we to what is make have don't believe

as it. our exacerbating we patients first thing toxicities. we're said, make that all on half of aza-ven -- is We not look we drugs for to sure tolerating have go as aza-ven to those However, difficulty to going add we're to

for, look first, tolerable drug always you we've efficacy, a with got think make let's that sure combination. but first that's I in things

Li Wang Watsek

are data setting your that potentially the AML? maybe collecting off-label could in points any on what support use? thoughts you And Are maintenance

James Dentzer

is first that What do Well, we drug target that, obviously, use have for is don't we do companies and look but something is that. safe. a off-label happens, foremost,

that compelling sure drugs. measure long you've profile provide for from unique of point, got make can of efficacy can't you a drug chronically be efficacy can your other then taken has and time. want And to we a that you get that Second, a so to periods third,

Some we're others aggressive, quite like indications indolent. fairly AML but are Waldenstroms the like going of are after

I X We now. drug have a over that's been patient on for, years believe,

it it setting. can we drug lab. are to long in emavusertib, for boxes. X so in a hope check And record. These safety The in good looks been looks, really a were tested to as of patients this able you I of days kind It drug still of think we've XXX provide track though drug a humans, of maintenance take got you drug does clinical far, profile. early but same seeing for as time And development developer. in that's though almost trifecta period a we've So efficacy have the that's, a course, over looks great the that that the as all

Operator

Yale Next question Laidlaw Jen & comes from of Company.

Yale Jen

you MDS, MDS, have line, to to the but high-risk move interested study be Jim, second your talked for will you that the waiting VERONA about readout.

to what's think when best happen in and do takes what place your your And if at this the you Just that plan future? knowledge, and might sometime -- that point?

James Dentzer

Yes. Thank you, Yale. Appreciate the question.

is So you're though exactly did standard we do to agent effectiveness terrific. clinical see though, appears really right, activity. We Can as that a MDS, like AML to not so add as really we active. as this looks the with lymphoma, unique It's It care? benefit. we're this MDS, of the doing single provide aza-ven. combination as has looks anticancer leukemia, go AML, frontline and care can the standard opportunity in drug data in far which in and whether provides in of is has know of in MDS just what of would out in it put The in in compelling we've is. what it care it and just Well, or standard

gone past out of just might aza-ven. has were development this read a MDS ASH. to people little A think expecting with slower I it lot have

but do we ASCO for know it's be looking imminent. going do expect read are people out, Now than are you of any frank. when more We don't to those to

that be want if whether is the aza. benefit is If is to or reads to aza answer a reads in then add it's care a positively, to which what initiate wins, it whether aza-ven triplet doublet. those its VERONA of can out know negatively, to can it's a going standard we see setting. population frontline that And the or two the combo, And either you doublet so we if in we of aza-ven; out like, MDS

So we those it as we'll in anticipating we're frontline soon have results, And are. MDS well. as you as to study be in looking a combination eagerly initiate as

Yale Jen

you meeting later that FDA here could And we the event? AML much we this helpful. conduct of That's stage year? this talk you about -- of you after the very next earlier, to Great. Or question anticipate second sort thought the guys to is a expecting Okay. may XXXX be later were data. that meeting development my potentially anticipate -- this Do a happen with

James Dentzer

I of quickly can't how to on going that we're speak really So have meeting. behalf FDA, the

very in having course, possible. interested are, it soon as as We of

really have as I kind interested the is, as the efficacy PCNSL like provide to benefit drug we've be The and wherever be to all testing that to be may a FDA it able that safety of of And are. likely there got add drug has receptive to think areas FDA seems we great we're a ought should second-line in profile, investigators in no where are drugs that our that approved. that.

FDA that FDA somewhat depending be tell quickly quickly the you on results of you a subject and being when results lot to know, able can the of forward guidelines moving got the drugs really we as looking So have to forward end. to can. call their But if what we'd apply as these that XX as have they got course, are in meetings. we be in a as you and possible. can consistent how push as of kind that to docket, we're But we've FDA's we'd the to soon seen it's together, to range, patients what of XX past, upon as And as the we get a with soon on sufficient probably about we've then, forward scheduling so when number we has getting, look those meeting

Yale Jen

could the question. in the this directional last expenses terms comparing guidance 'XX. operating tackle directionally -- of of know I guys you XXXX to of just one Okay. Great. do typically housekeeping in terms give Maybe expenses. year suggestion you give more not sort operating But

James Dentzer

I ask on Diantha Why in that. Yes. don't chime to

Diantha Duvall

Jim. Thanks,

mean, I believe yes, going are expenses to that we remain our consistent. So operating relatively

timing As chunky. up may us guided, fairly depending a I to to consistent into bit we've should of kind some things burn so gets the $XX think on of tend of in little that and more us that cash to a be peak XX% rate But XX%, to other manufacturing it 'XX, year-over-year. be you million gives XX% expect

Operator

The Truist Bill of Securities. comes from question Jahangiri next

Billal Jahangiri

wondering could for from the Congratulations. you AML interest anything were what strategic the bars if the about just us We there remind at or one? your then -- And for for us were also patients any that enrolling, you're could would study triplet if in be JPM partnership end. you tell

James Dentzer

Sure. Bill. Thanks,

conversations on the that imagine, got the in the of you in at think And investigator if with the seen I people we everywhere partnering potential can we've many drug And with kind mirrors having that would imagine we've think are interest go could course, we broadly trials. side that interest work. our like can So to it as participating some we side where always point, of partners. this

wherever a going and all sense turbocharge too academic to with and afford can't in started lymphoma small, studies other Curis just and that we with MDS as AML in So afford the those run indications across that's to We areas mentioned, partner, with in a some can't and clinical by frontline have leukemia, gets tumor centers. number just in of BTK tumors. solid our a been book both areas. help of At efforts setting And But NCI are point, solid it's those studied there -- now used, to in in I we're drug melanoma. bank manpower. make

that unlikely get have get that did melanoma it's at I'd don't Curis going for think say only -- will we the any rights, sense. we're give that, and data. stay timing where think deal I we a guidance I could to strike as me, of And I we're company point, forward, drug, recognized on question? part not up we but looks just providing be a that. And tuned. in But make is really and to drug, Going some that's compelling not would the to you giving your This remind second say Bill, we

Billal Jahangiri

-- Yes, yes, for the triplet.

eligibility what the look sure patients really not I'm So the and like criteria.

wondering you benchmarks. success what us be and for was the overall would I like if just tell there So bar just could

James Dentzer

the bar really at mentioned it's bar Watsek to is early Right. Thank Cantor, think a think days. -- as safety Yes, you. I in Li the I I

look tough. but their patients doublet cognizant it's to profiles or all When effective, ibrutinib aza-ven that are they're tolerate. are that these -- the for matter, is drugs are aza-ven with, of combining drugs we're for difficult safety that We the at we whether

so to And with of first we we that it regimen if tolerate combine a worse. take and we're make order business, want those, difficult to going the to sure make don't

easily first, first out the to but to make overlap we're need So no profile, thing we an that's things and have so. test looking of first. patients safety in that, sure there's It's believe we for reason that

that cancer IRAKX, the able above target Now is that that in with clinic of of be going safety, can all to And show pass to standard the date, novel to in whenever that's run. see recapitulate that the for in you're to going and of we're looking yield current hurdle, if that, for home you're once can to efficacy. And and looking been addressing does do think driver do we've that be triplet addressing want of emavusertib, efficacy the and course, preclinical what experience studies I care. other of replicate you we beyond to signs we this our incremental that adding that able

So first, first for course, to helpful. efficacy well. that's we're Hopefully, going But look safety. as of things

Billal Jahangiri

guess about grow? data that duration sure CNS need you're I'm make I lymphoma, Wonderful. last just incorrectly. verify, just this thinking one want Great. one. Yes. not hitting already in to set right? like to seems And the bar It I We

James Dentzer

Yes.

think we right. I -- exactly

data fantastic. I looks think the set

would better was X In it But need. bit fact, [ days, standard we than it's ]. early quite a

think had go to show, be going today, then were XX able go XX need if on patients to to BTK. primary lymphoma, going said, treating CNS we we on as and chemo, what as I that you XX go methotrexate with I that to to high-dose had to patients, failed and So They're they're ibrutinib. you

on of based ibrutinib it, rate up call You'd study bit, round been of done CR patients on XX%. little to those the XX%, a expect X a XX monotherapy, get let's so that's response largest

X patients of we're X. Because all our more line. our have CR more CRs X to patients. ibrutinib. of remember, out add In need the to case, match patients and XX We earlier just You'd failed of get XX X need

ibrutinib. them You'd you with expect X of rechallenge XX, if out

X So discussion that of case, with out compelling or CR got more can good have of frankly, match in XX a the with X our we've think to out of if think, pretty get we XX prior really patients, next that. line I I And FDA. odds our are

Operator

the Jim over remarks. for Chief would question-and-answer to concludes I closing any Executive turn like Officer, session. President and company's Dentzer, This conference to the back our

James Dentzer

for always, and joining and ongoing in partners and to hard Aurigene for forward at our at to our NCI for updating participating today's support. We you, our and commitment the to And their Thank help call. trials, you, Curis the Andrea, thank look clinical again as families soon. and you you team thank to work and patients Operator? everyone, their

Operator

disconnect. concluded. The for may you Thank you today's presentation, conference has now now attending and

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.